协同组装纳米粒子通过充分利用分子识别和自我组装来实现阿尔茨海默病的多目标组合疗法
Wen-Bo Li1,2, Lin-Lin Xu1,3, Si-Lei Wang1,3
1College of Chemistry, Key Laboratory of Functional Polymer Materials (Ministry of Education), Nankai University, Tianjin, 300071, China.
Advanced materials (Deerfield Beach, Fla.)
|April 25, 2024
概括
这项研究介绍了一种新型的超分子系统,使用两性卡利沙伦同时向多种阿尔茨海默病 (AD) 病理,包括粉样β (Aβ) 和氧化应激. 这种方法有效地改善了AD小鼠模型中的认知障碍.
科学领域:
- 生物化学 生物化学
- 神经科学是一个神经科学.
- 材料科学 材料科学 材料科学
背景情况:
- 阿尔茨海默病 (AD) 复杂的病理需要多目标治疗策略,因为单干预方法的局限性.
- 超分子策略提供可调节的平台,用于整合多种治疗功能,解决AD异质性.
研究的目的:
- 开发一种多功能超分子系统,同时干预关键阿尔茨海默病 (AD) 病理途径.
- 调查针对粉样β (Aβ) 纤维化和氧化应激的多功能系统的治疗疗效.
主要方法:
- 与阿斯科尔比尔棕酸盐一起组装瓜尼尼改性卡力沙,并加入二酸盐.
- 评估该系统抑制Aβ产生/聚合,分解Aβ纤维,增强Aβ清除和调节氧化应激的能力.
- 在5×FAD阿尔茨海默病小鼠模型中评估认知功能和神经病理标记.
主要成果:
- 开发的超分子系统有效地抑制了Aβ的产生和聚合,促进了Aβ的清除,并减轻了氧化应激.
- 在接受该系统治疗的5×FAD小鼠中观察到认知障碍的显著改善.
- 在接受治疗的小鼠中证实了Aβ斑块负荷的减少,神经炎症和神经元亡.
结论:
- 提出的超分子多功能整合策略为阿尔茨海默病 (AD) 组合疗法提供了一个可调和和适应的平台.
- 这种方法表明,有很大的潜力来推进对AD等复杂的神经退行性疾病的有效治疗方法的开发.
相关概念视频
01:22Alzheimer's Disease: Treatment
183
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
183
01:26Alzheimer's Disease: Overview
468
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
468